Neonatal autoimmune hemolytic anemia

Advocacy intelligence hub — real-time data for patient organizations

View full disease page →Search clinical trials →
Download CSV

At a Glance

Live from database

Regulatory Watchboard

2 events
Jan 2023Evaluation of a Smartphone-based Screening Tool (Picterus JP) for Neonatal Jaundice (Chicago)

Picterus AS — NA

TrialRECRUITING
Feb 2022Enjaymo: FDA approved

To decrease the need for red blood cell (RBC) transfusion due to hemolysis in adults with cold agglutinin disease (CAD)

FDAcompleted

Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Financial Assistance

FINANCIAL LANDSCAPE SUMMARY

0

Total programs

No financial assistance programs currently listed for Neonatal autoimmune hemolytic anemia.
Check the disease page for updates →

Approved Treatments

1 FDA-approved

Enjaymo

(SUTIMLIMAB-JOME)Orphan drug

Recordati Rare Diseases, Inc.

Classical Complement Pathway Inhibitor [EPC]

12.1 Mechanism of Action Sutimlimab-jome is an immunoglobulin G (IgG), subclass 4 (IgG4) monoclonal antibody (mAb) that inhibits the classical complem...

Approved Feb 2022FDA label ↗

View full treatment details on disease page →

Clinical Trial Landscape

No active clinical trials currently recruiting for Neonatal autoimmune hemolytic anemia.
Search all trials →
Search clinical trials for Neonatal autoimmune hemolytic anemia

Recent News & Research

No recent news articles indexed yet for Neonatal autoimmune hemolytic anemia.
Search PubMed for Neonatal autoimmune hemolytic anemia

Browse all Neonatal autoimmune hemolytic anemia news →

Specialist Network

Top 6 by expertise

View all Neonatal autoimmune hemolytic anemia specialists →

Quick Actions